ClinicalTrials.gg
CompletedNCT00946192Updated Jun 11, 2021Results posted

Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes

A Phase 3 interventional study of Transdermal 17Beta-estradiol, progesterone and Ethinyl Estradiol + Desogestrel in Exercise-related Amenorrhea, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to female participants aged 14 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Massachusetts General Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
14 Years to 21 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Enrollment
8th of 30
121 · median 37
Started
2009
with 1 other
Phase 3
5 of 43
1 open now
Registered
17th of 43
by date
Lead sponsor
8 of 43
Massachusetts General Hospital

Among the 43 studies in Amenorrhea with a site in United States, this one is the 8th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2009, is one of 5 in phase 3, and was the 17th registered.

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 14 Years to 21 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

One aim of this study is to determine changes in body composition and hormones that differentiate athletes who stop getting their periods versus those who continue to get their periods and non-athletes. The second aim of this study is to determine whether transdermal or oral estrogen (versus no estrogen) is effective in increasing bone density and improving bone microarchitecture in adolescent athletes who are not getting their periods and are thus estrogen deficient. The investigators hypothesize that transdermal estrogen will be more effective than oral estrogen or no estrogen in improving bone health in amenorrheic adolescent athletes.

Read the detailed description

As many as 25% of adolescent and young adult endurance athletes develop amenorrhea, and factors that cause amenorrhea to occur in some, but not all, athletes have not been well characterized. Recent data indicate the critical importance of a negative energy balance state and leptin in regulating the Hypothalamic-pituitary-gonadal (H-P-G) axis. However, these factors do not completely account for alterations in this axis, and other contributing factors are unclear. Our preliminary data indicate the importance of low fat mass and fat related hormones in mediating hypogonadism in young athletes. This study will confirm these data and determine whether low fat mass and altered levels of adipokines, such as leptin and adiponectin, and hormones regulated by fat mass, such as ghrelin and peptide YY (PYY), determine alterations in LH pulsatility. A very concerning impact of amenorrhea in athletes is low bone mineral density (BMD). Preliminary data indicate lower BMD in adolescent athletes with amenorrhea (AA) compared with eumenorrheic athletes (EA) and non-athletic controls. The high prevalence of AA in adolescents is particularly concerning, because this population is potentially at greater risk as it is actively accruing bone. Of importance, bone microarchitecture, a better predictor of bone strength than BMD, has not been studied in AA. Because pubertal increases in estrogen are integral to optimizing peak bone mass, and AA is characterized by hypoestrogenism, this randomized study of transdermal estrogen versus oral estrogen or no estrogen will also examine whether estrogen replacement increases BMD and improves bone microarchitecture in adolescent AA 14-21 years old. EA and sedentary controls will be followed without intervention for this period. Despite the prevalent practice of prescribing oral contraceptives in AA, there is a paucity of data regarding benefits of this intervention in teenagers. Because transdermal estrogen, unlike oral estrogen, does not suppress IGF-1, an important bone anabolic factor, we expect effects of transdermal estrogen to exceed those of oral estrogen or no therapy. In addition, preliminary data indicate that low fat mass and alterations in fat related hormones may contribute to decreased bone accrual rates in athletes, and will be confirmed in this study. To summarize, a better understanding of the pathophysiology of reproductive dysfunction is critical to develop therapeutic strategies that will normalize the reproductive axis and bone accrual, and these are the questions that this study aims to answer.

03

Conditions studied

  • Exercise-related Amenorrhea

Keywords

  • Amenorrhea
  • Adolescent
  • Endurance
  • Athletes
  • Females
  • Osteopenia
  • Osteoporosis
  • Estrogen
04

Who can participate

Ages eligible
14 Years to 21 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females 14-21 years old Note: Our pilot data are reassuring in that young women 18-25 years old with hypothalamic amenorrhea are not adversely affected with estrogen use. In fact, in our prospective study, beneficial effects were observed both in young women 18-25 years old using oral estrogen, and in 14-18 year old adolescent girls using transdermal estrogen. We therefore feel that including girls in the 14-21 year age range will not be hazardous to their bone health. In fact, given the lack of data in this age group, it is important to study younger women and teenagers rather than extrapolate data from studies in adults to this younger population. Hormone dynamics differ in teenagers compared with adults, and bone mass accrual is even more dependent on estrogen and IGF-1 in younger than older women who have already achieved peak bone mass.
  • Bone age (BA) >15 years Note: 99% of adult height is achieved at a BA of 15 years, thus estrogen replacement will not result in stunting of height potential after this age. Although we could have chosen to include girls with a BA >14 in this study, we are limiting this to girls with a BA of >15 years. This is because 2% of growth potential persists at a BA of 14 years, versus only 1% at a BA of 15 years (\~0.6" of potential height (130)). Thus, to avoid potential stunting of growth potential with estrogen replacement, we have chosen to include girls with BA of > 15 years.
  • between 10th-90th percentiles for age.
  • Amenorrhea (for AA): absence of menses for > three months (74) within a period of oligomenorrhea (cycle length > six weeks) for >six months, or absence of menarche at >16 years.
  • Eumenorrhea (EA and controls): > nine menses (cycle length 21-35 days) in preceding year.
  • Non-athlete healthy controls will be eligible if weight bearing exercise activity is less than two hours a week and if they are not participating in organized team sports.
  • Endurance athletes Note: severity of low BMD and menstrual dysfunction differ by kind of exercise and activity. For example, runners have a higher prevalence of menstrual irregularity than swimmers and cyclists (131). By limiting enrollment to endurance athletes, we will eliminate variability from the type of activity. Endurance training is defined as > 4 h of aerobic weight-bearing training of the legs or specific endurance training weekly, or > 20 miles of running weekly for a period of > 6 months in the last year.

Exclusion criteria

Exclusion Criteria:

  • Other conditions that may affect bone metabolism
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    Estrogen Patch

    17Beta-estradiol transdermal patch twice weekly application for 12 months

    Drug: Transdermal 17Beta-estradiol, progesterone

  • Active comparator
    Estrogen Pill

    One pill containing estrogen and progesterone taken daily for 21 days followed by placebo pills only for 7 days; regimen repeated for 12 months.

    Drug: Ethinyl Estradiol + Desogestrel

  • Sham comparator
    Control

    Elemental calcium 1200 mg and Vit D 400 IU taken orally daily

    Dietary Supplement: Sham Comparator

Interventions

  • DrugTransdermal 17Beta-estradiol, progesterone

    Drug pages: EstradiolStudies of EstradiolEstradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ProgesteroneStudies of ProgesteroneProgesterone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily

    Also known as: Vivelle Dot transdermal patch, Prometrium

  • DrugEthinyl Estradiol + Desogestrel

    Drug pages: Ethinyl EstradiolStudies of Ethinyl EstradiolEthinyl Estradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DesogestrelStudies of DesogestrelDesogestrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily

    Also known as: Apri

  • Dietary supplementSham Comparator

    Elemental calcium 1200 mg and Vit D 400 IU taken orally daily

06

What researchers measure

Primary outcomes

  1. Change in Lumbar Bone Mineral Density

    Change in bone density with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes

    Time frame: 12 months

Secondary outcomes

  1. Change in Total Volumetric Bone Mineral Density (Tibia)

    Change in total volumetric bone density at the tibia with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes

    Time frame: 12 months

07

Results

Posted Mar 18, 2020

Participant flow

Participant flow — Overall Study
MilestoneEstrogen PatchEstrogen PillControl
Started434038
Completed252226
Not completed181812
Withdrew: Lost to follow-up6119
Withdrew: Withdrawal by subject1073
Withdrew: Did not start medication200

Outcome measures

PrimaryChange in Lumbar Bone Mineral Density

Change in bone density with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes

Time frame:
12 months
Reported as:
Mean · g/cm^2
Change in Lumbar Bone Mineral Density
g/cm^2Estrogen PatchEstrogen PillControl
Change in Lumbar Bone Mineral Density0.025 ± 0.0110.008 ± 0.0110.012 ± 0.012
Statistical analysis
  • Estrogen Patch vs Estrogen Pill vs Control · Mixed Models Analysis · p = 0.039
SecondaryChange in Total Volumetric Bone Mineral Density (Tibia)

Change in total volumetric bone density at the tibia with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes

Time frame:
12 months
Reported as:
Mean · mg HA/cm^3
Change in Total Volumetric Bone Mineral Density (Tibia)
mg HA/cm^3Estrogen PatchEstrogen PillControl
Change in Total Volumetric Bone Mineral Density (Tibia)7.01 ± 3.061.17 ± 3.053.71 ± 4.44
Statistical analysis
  • Estrogen Patch vs Estrogen Pill vs Control · Mixed Models Analysis · p = 0.018

Adverse events

Collected over 1 year. Non-serious events are listed at a 0.1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Estrogen Patch0/43 (0%)3/43 (7%)10/43 (23.3%)
Estrogen Pill0/40 (0%)0/40 (0%)13/40 (32.5%)
Control0/38 (0%)1/38 (2.6%)1/38 (2.6%)
Most frequent serious events
Most frequent serious events
EventEstrogen PatchEstrogen PillControl
Fractures or sprainsEndocrine disorders3/430/400/38
Sinus surgeryRespiratory, thoracic and mediastinal disorders0/430/401/38
Most frequent other events
Showing 10 of 21
Most frequent other events
EventEstrogen PatchEstrogen PillControl
NauseaGastrointestinal disorders0/432/400/38
Vasovagal responseVascular disorders0/432/400/38
HeadacheNervous system disorders2/431/400/38
BloatingGeneral disorders2/430/400/38
Upper respiratory symptomsRespiratory, thoracic and mediastinal disorders0/430/401/38
FatigueGeneral disorders0/431/400/38
Breast tendernessEndocrine disorders1/431/400/38
Fluid retentionMetabolism and nutrition disorders0/431/400/38
Early mensesEndocrine disorders0/431/400/38
Yeast infectionInfections and infestations0/431/400/38

Baseline characteristics

Athletes with amenorrhea

Age, Continuous
Age, Continuous(years)Estrogen PatchEstrogen PillControlTotal
Mean19.86 ± 0.4020.30 ± 0.4419.35 ± 0.3819.84 ± 0.41
Sex: Female, Male
Sex: Female, Male(Participants)Estrogen PatchEstrogen PillControlTotal
Female434038121
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Estrogen PatchEstrogen PillControlTotal
Hispanic or Latino0022
Not Hispanic or Latino434036119
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Estrogen PatchEstrogen PillControlTotal
American Indian or Alaska Native1001
Asian4015
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White373835110
More than one race1225
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Estrogen PatchEstrogen PillControlTotal
United States434038121
BMI
BMI(kg/m^2)Estrogen PatchEstrogen PillControlTotal
Mean20.45 ± 0.3520.80 ± 0.3920.75 ± 0.3420.67 ± 0.36
08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Publications

  • Ackerman KE, Singhal V, Slattery M, Eddy KT, Bouxsein ML, Lee H, Klibanski A, Misra M. Effects of Estrogen Replacement on Bone Geometry and Microarchitecture in Adolescent and Young Adult Oligoamenorrheic Athletes: A Randomized Trial. J Bone Miner Res. 2020 Feb;35(2):248-260. doi: 10.1002/jbmr.3887. Epub 2019 Nov 7. PubMed 31603998 ↗
  • Plessow F, Singhal V, Toth AT, Micali N, Eddy KT, Misra M. Estrogen administration improves the trajectory of eating disorder pathology in oligo-amenorrheic athletes: A randomized controlled trial. Psychoneuroendocrinology. 2019 Apr;102:273-280. doi: 10.1016/j.psyneuen.2018.11.013. Epub 2018 Nov 16. PubMed 30639922 ↗
  • Singhal V, Ackerman KE, Bose A, Flores LPT, Lee H, Misra M. Impact of Route of Estrogen Administration on Bone Turnover Markers in Oligoamenorrheic Athletes and Its Mediators. J Clin Endocrinol Metab. 2019 May 1;104(5):1449-1458. doi: 10.1210/jc.2018-02143. PubMed 30476179 ↗
  • Ackerman KE, Singhal V, Baskaran C, Slattery M, Campoverde Reyes KJ, Toth A, Eddy KT, Bouxsein ML, Lee H, Klibanski A, Misra M. Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial. Br J Sports Med. 2019 Feb;53(4):229-236. doi: 10.1136/bjsports-2018-099723. Epub 2018 Oct 9. PubMed 30301734 ↗
  • Baskaran C, Cunningham B, Plessow F, Singhal V, Woolley R, Ackerman KE, Slattery M, Lee H, Lawson EA, Eddy K, Misra M. Estrogen Replacement Improves Verbal Memory and Executive Control in Oligomenorrheic/Amenorrheic Athletes in a Randomized Controlled Trial. J Clin Psychiatry. 2017 May;78(5):e490-e497. doi: 10.4088/JCP.15m10544. PubMed 28297591 ↗
  • Ackerman KE, Slusarz K, Guereca G, Pierce L, Slattery M, Mendes N, Herzog DB, Misra M. Higher ghrelin and lower leptin secretion are associated with lower LH secretion in young amenorrheic athletes compared with eumenorrheic athletes and controls. Am J Physiol Endocrinol Metab. 2012 Apr 1;302(7):E800-6. doi: 10.1152/ajpendo.00598.2011. Epub 2012 Jan 17. PubMed 22252944 ↗
  • Ackerman KE, Nazem T, Chapko D, Russell M, Mendes N, Taylor AP, Bouxsein ML, Misra M. Bone microarchitecture is impaired in adolescent amenorrheic athletes compared with eumenorrheic athletes and nonathletic controls. J Clin Endocrinol Metab. 2011 Oct;96(10):3123-33. doi: 10.1210/jc.2011-1614. Epub 2011 Aug 3. PubMed 21816790 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2009 to primary completion in Feb 2020, 129 months.

Results were first posted in Mar 2020, 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2009
First posted
Jul 24, 2009
StartActual
May 2009
Primary completionActual
Feb 2020
CompletionActual
Apr 2021
Results first posted
Mar 18, 2020
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00946192
Responsible party
Madhusmita Misra (Associate Professor of Pediatrics, Massachusetts General Hospital) — Principal investigator
First posted
Jul 24, 2009
Start date
May 2009
Primary completion
Feb 2020
Completion
Apr 2021
Results posted
Mar 18, 2020
Last update
Jun 11, 2021

Study contacts

Madhusmita Misra, MD, MPH
principal investigator · Massachusetts General Hospital Pediatric Neuroendocrine Unit and Harvard Medical School

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Progesterone

Start the discussion